Keith W. Pratz

Clinical trials

• Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

  Principal investigator · Active not recruiting · Phase 2

  National Cancer Institute (NCI)

  2018–2026
• Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

  Principal investigator · Completed · Phase 1

  National Cancer Institute (NCI)

  2008–2016
• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2024–2029
• Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  Site PI · Recruiting · Phase 3

  Alliance for Clinical Trials in Oncology

  2017–2027